Treatment of metastatic hormone dependent breast cancer with combination palbociclib and letrozol – case report

01/2020 Special Edition

MUDr. Věra Benešová

Komplexní onkologické centrum nemocnice Jihlava



Anti-tumor effect of CDK4/6 inhibitors in combination with hormone therapy significantly prolong progression free survival with prolongation time of lifetime. The use of this combination therapy in routine clinical practice fundamentally changes the treatment options of our patients.


Key words

metastatic hormone dependent breast cancer, aromatase inhibitor letrozole, CDK4/6 inhibitor, palbociclib, Ibrance



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...